PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types

por Chia, Pei Ling, Ang, Koon Hwee, Thura, Min, Zeng, Qi
Publicado 2023

Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs

por Thura, Min, Sng, Joel Xuan En, Ang, Koon Hwee, Li, Jie, Gupta, Abhishek, Hong, Jimmy Ming, Hong, Cheng William, Zeng, Qi
Publicado 2021

PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse

por Thura, Min, Ye, Zu, Al-Aidaroos, Abdul Qader, Xiong, Qiancheng, Ong, Jun Yi, Gupta, Abhishek, Li, Jie, Guo, Ke, Ang, Koon Hwee, Zeng, Qi
Publicado 2021

Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse

por Thura, Min, Ye, Zu, Al-Aidaroos, Abdul Qader, Xiong, Qiancheng, Ong, Jun Yi, Gupta, Abhishek, Li, Jie, Guo, Ke, Ang, Koon Hwee, Zeng, Qi
Publicado 2021

ELTD1 Activation Induces an Endothelial-EMT Transition to a Myofibroblast Phenotype

por Sheldon, Helen, Alexander, John, Bridges, Esther, Moreira, Lucia, Reilly, Svetlana, Ang, Koon Hwee, Wang, Dian, Lin, Salwa, Haider, Syed, Banham, Alison H., Harris, Adrian L.
Publicado 2021

Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody

por Loh, Amos Hong Pheng, Thura, Min, Gupta, Abhishek, Tan, Sheng Hui, Kuan, Kelvin Kam Yew, Ang, Koon Hwee, Merchant, Khurshid, Chang, Kenneth Tou En, Yon, Hui Yi, Chen, Yong, Cheng, Mathew Hern Wang, Mahadev, Arjandas, Ng, Matthew Chau Hsien, Seng, Michaela Su-Fern, Iyer, Prasad, Chia, Pei Ling, Soh, Shui Yen, Zeng, Qi
Publicado 2023